Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

British Journal of Haematology

Volumn 167, Issue 4, 2014, Pages 563-565

  Reeder, Craig B ^a   Reece, Donna E ^b   Kukreti, Vishal ^b   Mikhael, Joseph R ^a   Chen, Christine ^b   Trudel, Suzanne ^b   Laumann, Kristina ^c   Vohra, Harjot ^b   Fonseca, Rafael ^a   Bergsagel, P Leif ^a   Leis, Jose F ^a   Tiedemann, Rodger ^b   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Bortezomib; Cyclophosphamide; Myeloma; Survival

Indexed keywords

ACICLOVIR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; QUINOLONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; COHORT ANALYSIS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; LETTER; LONG TERM SURVIVAL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; ADOLESCENT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SURVIVAL RATE;

EID: 84916205635     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13004     Document Type: Letter

References (10)

1. Dispenzieri, A., Rajkumar, S.V., Gertz, M.A., Fonseca, R., Lacy, M.Q., Bergsagel, P.L., Kyle, R.A., Greipp, P.R., Witzig, T.E., Reeder, C.B., Lust, J.A., Russell, S.J., Hayman, S.R., Roy, V., Kumar, S., Zeldenrust, S.R., Dalton, R.J. & Stewart, A.K. (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings, 82, 323-341.
2. Harousseau, J.-L., Attal, M. & Avet-Loiseau, H. (2009) The role of complete response in multiple myeloma. Blood, 114, 3139-3146.
3. Jakubowiak, A., Dytfeld, D., Griffith, K.A., Lebovic, D., Vesole, D., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., Stockerl-Goldstein, K., Asra Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M. & Vij, R. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801-1809.
4. Khan, M.L., Reeder, C.B., Kumar, S.K., Lacy, M.Q., Reece, D.E., Dispenzieri, A., Gertz, M.A., Greipp, P., Hayman, S., Zeldenhurst, S., Dingli, D., Lust, J., Russell, S., Laumann, K.M., Mikhael, J.R., Leif Bergsagel, P., Fonseca, R., Vincent Rajkumar, S. & Keith Stewart, A. (2012) A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 156, 326-333.
5. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
6. Kumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 4375-4382.
7. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N.A., Spong, J.E., Piza, J.G., Zepeda, V.H., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 23, 1337-1341.
8. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Lauman, K., Hentz, J., Pirooz, N.A., Piza, J.G., Tiedemann, R., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2010) Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-3417.
9. Richardson, P., Weller, E., Lonial, S., Jakubowiak, A., Jagannath, S., Raje, N., Avigan, D., Xie, W., Ghobrial, I., Schlossman, R., Mazumder, A., Munshi, N., Vesole, D., Joyce, R., Kaufman, J., Doss, D., Warren, D., Lunde, L., Kaster, S., DeLaney, C., Hideshima, T., Mitsiades, C., Knight, R., Esseltine, D. & Anderson, K. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy inpatients with newly diagnosed multiple myeloma. Blood, 116, 679-686.
10. Srivastava, G., Rana, V., Lacy, M.Q., Buadi, F.K., Hayman, S.R., Dispenzieri, A., Gertz, M.A., Dingli, D., Zeldenrust, S., Russell, S., McCurdy, A., Kapoor, P., Kyle, R., Rajkumar, S.V. & Kumar, S. (2013) Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia, 27, 2062-2066.